SCIB

Keynote speakers presented Nevisense at the 2024 Winter Clinical Dermatology Conference in Miami

Retrieved on: 
Monday, February 19, 2024

STOCKHOLM, Feb. 19, 2024 /PRNewswire/ -- SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of augmented intelligence-based solutions for skin disorders participated at the 2024 Winter Clinical Dermatology Conference in Miami.

Key Points: 
  • STOCKHOLM, Feb. 19, 2024 /PRNewswire/ -- SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of augmented intelligence-based solutions for skin disorders participated at the 2024 Winter Clinical Dermatology Conference in Miami.
  • The second annual Winter Clinical Miami conference is a 4-day CME course that educates dermatologists on innovative news within Medical, and Surgical Dermatology.
  • At the conference, SciBase presented its product Nevisense - an AI-powered detection enhancement technology that improves the ability for early detection of melanoma at point of care.
  • Attendees had the opportunity to learn about Nevisense in the scientific sessions where Nevisense was presented and gain valuable insight on how to improve patient outcomes by integrating Nevisense into their clinical practices.

Welcome to SciBase Capital Markets Day 2024

Retrieved on: 
Thursday, January 25, 2024

STOCKHOLM, Jan. 25, 2024 /PRNewswire/ -- SciBase Holding AB ("SciBase") [STO: SCIB], a pioneer in early detection and prevention in dermatology hereby invites investors, analysts, and financial media to SciBase Capital Markets Day today on January 25, 2024.

Key Points: 
  • STOCKHOLM, Jan. 25, 2024 /PRNewswire/ -- SciBase Holding AB ("SciBase") [STO: SCIB], a pioneer in early detection and prevention in dermatology hereby invites investors, analysts, and financial media to SciBase Capital Markets Day today on January 25, 2024.
  • During SciBase's Capital Markets Day, Pia Renaudin, who assumed the role of CEO in October 2023, will provide insights into SciBase's future trajectory, and unveil an updated strategic outlook, and long-term strategic goals.
  • The presentations will underscore the company's focus on the USA and shed light on SciBase's ongoing expansion into promising new markets.
  • Although the Company has a strategic focus on the USA, Germany continues to be an important and profitable market for SciBase.

Welcome to SciBase Capital Markets Day 2024

Retrieved on: 
Tuesday, January 9, 2024

STOCKHOLM, Jan. 9, 2024 /PRNewswire/ -- SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of augmented intelligence-based solutions for skin disorders hereby invites investors, analysts, and financial media to SciBase capital markets day on January 25, 2024.

Key Points: 
  • STOCKHOLM, Jan. 9, 2024 /PRNewswire/ -- SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of augmented intelligence-based solutions for skin disorders hereby invites investors, analysts, and financial media to SciBase capital markets day on January 25, 2024.
  • During SciBase's Capital Markets Day, Pia Renaudin, who assumed the role of CEO in October 2023, will provide insights into SciBase's future trajectory, and unveil an updated strategic outlook, and long-term strategic goals.
  • The presentations will underscore the company's focus on the USA and shed light on SciBase's ongoing expansion into promising new markets.
  • Two external speakers will participate in the event, further supporting the US role in the SciBase strategy going forward.

SciBase capital markets day 2024 - save the date

Retrieved on: 
Thursday, December 28, 2023

STOCKHOLM, Dec. 28, 2023 /PRNewswire/ -- SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, hereby invites investors, analysts and financial media to SciBase capital markets day on January 25, 2024.

Key Points: 
  • STOCKHOLM, Dec. 28, 2023 /PRNewswire/ -- SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, hereby invites investors, analysts and financial media to SciBase capital markets day on January 25, 2024.
  • During SciBase's capital markets day, Pia Renaudin, CEO since October 2023, will discuss SciBase's way forward, updated strategy and long-term goals.
  • The presentations will focus on the USA as well as SciBase's ongoing establishment in new promising markets.
  • Pinnacle, an independent specialist company in the US reimbursement system, will explain the SciBase path towards reimbursement in the US.

SciBase initiates pilot with Bare Dermatology to advance skin cancer detection in Texas

Retrieved on: 
Monday, September 25, 2023

STOCKHOLM, Sept. 25, 2023 /PRNewswire/ -- SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders announced today that they have entered into a collaboration agreement with Bare Dermatology to pilot Nevisense in select locations in Texas.

Key Points: 
  • STOCKHOLM, Sept. 25, 2023 /PRNewswire/ -- SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders announced today that they have entered into a collaboration agreement with Bare Dermatology to pilot Nevisense in select locations in Texas.
  • Bare Dermatology is a dermatology practice group in the Greater Dallas area, with five offices and a team of nationally renowned dermatologists.
  • The agreement will provide Bare Dermatology with Nevisense, the only FDA-approved test for early melanoma detection at point-of-care.
  • We are pleased to collaborate with Bare Dermatology as we expand across the US to address the early detection of melanoma needs", said Pia Renaudin, appointed Chief Executive Officer of SciBase.

SCIB Reports Q4FY2023 Financial Results with Revenue of RM33.3 Million, Gross Profit of RM6.5 Million and Highlights Growth Opportunities

Retrieved on: 
Tuesday, August 29, 2023

Gross Profit grew by 73% to RM6.5 million from RM3.8 million in the corresponding period of the previous fiscal year.

Key Points: 
  • Gross Profit grew by 73% to RM6.5 million from RM3.8 million in the corresponding period of the previous fiscal year.
  • The Operating Loss was significantly reduced to RM18.2 million from RM47.1 million, and Loss Before Tax (LBT) improved to RM18.5 million from RM47.4 million in Q4FY2022.
  • In the Manufacturing segment, SCIB reported revenue of RM23.2 million, a year-to-date increase of 10%, with profit before tax of RM2.8 million.
  • The Construction/EPCC segment registered revenue of RM10.2 million, marking a 92% increase year-to-date, with loss before tax narrowed to RM4.5 million.

Sarawak Consolidated Commences Legal Action against Dynamic Prestige Consultancy

Retrieved on: 
Thursday, July 27, 2023

KUCHING, MALAYSIA, July 27, 2023 - (ACN Newswire) - Civil engineering specialist Sarawak Consolidated Industries Berhad (SCIB) today announced that it has initiated legal proceedings against Dynamic Prestige Consultancy Sdn.

Key Points: 
  • KUCHING, MALAYSIA, July 27, 2023 - (ACN Newswire) - Civil engineering specialist Sarawak Consolidated Industries Berhad (SCIB) today announced that it has initiated legal proceedings against Dynamic Prestige Consultancy Sdn.
  • As part of the agreement, Dynamic Prestige Consultancy Sdn.
  • However, to date, Dynamic Prestige Consultancy Sdn.
  • We remain confident in our legal position and are committed to ensuring the best outcome for our shareholders and stakeholders."

SCIB Celebrates Sarawak Day With Life-Saving Blood Donation Drive

Retrieved on: 
Friday, July 21, 2023

KUCHING, MALAYSIA, July 21, 2023 - (ACN Newswire) - Civil engineering specialist Sarawak Consolidated Industries Berhad ("SCIB" or the "Company") is pleased to announce that they have organised their annual blood donation drive in collaboration with the Sarawak General Hospital Blood Bank in honor of Sarawak Day.

Key Points: 
  • KUCHING, MALAYSIA, July 21, 2023 - (ACN Newswire) - Civil engineering specialist Sarawak Consolidated Industries Berhad ("SCIB" or the "Company") is pleased to announce that they have organised their annual blood donation drive in collaboration with the Sarawak General Hospital Blood Bank in honor of Sarawak Day.
  • The initiative, known as "SCIB Blood Donation Day", is part of the company's ongoing commitment to giving back to society.
  • "This blood donation drive not only aligns with our social responsibility but also embodies the spirit of Sarawak Day - unity and care for one another.
  • The SCIB Blood Donation Day is one of many initiatives demonstrating how SCIB fulfils its ESG commitments while making a real difference to people's lives.

SCIB Announces Restructuring at Board Level

Retrieved on: 
Wednesday, June 28, 2023

Dr. Dang Nguk Ling is an Independent Non-Executive Directors of APB Resources Berhad where Mr. Liaw also serves as an Executive Director.

Key Points: 
  • Dr. Dang Nguk Ling is an Independent Non-Executive Directors of APB Resources Berhad where Mr. Liaw also serves as an Executive Director.
  • SCIB also announced the resignation of Group Chief Executive Officer and Managing Director, Encik Rosland Bin Othman today as well as three Independent Non-Executive Directors, namely En.
  • I look forward to working closely with them as SCIB will certainly be able to leverage on their experience and expertise."
  • Nuraiman bin Shaiful Annuar well and thank them for their guidance and advice in their time as directors of SCIB."

SCIB Posts Revenue of RM32.4 Million for 3Q

Retrieved on: 
Thursday, May 25, 2023

On a segmental basis, the manufacturing division, which produces precast concrete and Industrialised Building System (IBS) building materials, recorded revenue of RM23.2 million in 3Q FY2023 compared with RM22.1 million in 3Q FY2022 and PBT of RM2.7 million compared with RM0.7 million.

Key Points: 
  • On a segmental basis, the manufacturing division, which produces precast concrete and Industrialised Building System (IBS) building materials, recorded revenue of RM23.2 million in 3Q FY2023 compared with RM22.1 million in 3Q FY2022 and PBT of RM2.7 million compared with RM0.7 million.
  • In 9M FY2023, the manufacturing segment recorded a cumulative revenue of RM68.9 million, as compared to RM64.9 million in 9M FY2022 and PBT RM4.8 million compared with RM0.97 million.
  • The engineering, procurement, construction, and commissioning (EPCC) division recorded a revenue of RM9.2 million in 3Q FY2023 compared with RM15.1 million in 3Q FY2022 and PBT of RM0.009 million compared with LBT of RM0.66 million.
  • The EPCC segment registered a cumulative revenue of RM29.4 million in 9M FY2023 compared with RM36.6 million with a cumulative LBT of RM1.44 million compared with LBT of RM1.74 million.